The Institute for Clinical and Economic Research aims to measure the value of drugs and aims to reduce the price of treatments that they deem to be low-value. Is this simply an academic exercises, or are payers paying attention? An article in CNBC sheds some light on the topic:
Asked about that analysis, Miller said: “We used the ICER report in our negotiations. Did we receive the ICER price? The answer is no, we didn’t.”
The ‘Miller’ above refers to Dr. Steve Miller, senior vice president and chief medical officer of Express Scripts.
It should not come as a surprise that insurance companies and pharmacy benefit managers are using all evidence at their disposal to try to drive down the price of prescription drugs.